Valuation models
price $420.07 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused404.09 – 717.82523.3620% undervaluedDCF · Perpetuity growth · 10y430.24 – 747.24550.9324% undervaluedDCF · EBITDA exit · 5y736.45 – 812.65773.5146% undervaluedDCF · EBITDA exit · 10y691.66 – 829.12757.0545% undervaluedP/E · peers390.02 – 1,485.46555.9024% undervaluedP/E · own history419.24 – 539.79504.4417% undervaluedPEG—427.942% undervaluedEV/EBITDA · peers267.65 – 728.63654.0636% undervaluedEV/Revenue · peers141.85 – 299.25241.4274% overvaluedEarnings power value342.52 – 579.98436.444% undervaluedDividend discount133.60 – 358.84202.20108% overvaluedWall St. consensus target—478.5012% belowCost of capital (WACC)—7.18%—
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. How the headline model is chosen.
Model value · DCF · Perpetuity growth · 5y
523.36
Elevance Health closed at $420.07 — undervalued by 20% vs model.
404.09the model's range717.82
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
202.20 – 773.51
Wall St. target
478.50 12% below
Below model, 1y
30 of 30 days
How it is valued
Valued asMature & stable
Low/slowing growth (~8% recent)Thin margins (2.8% net margin)Pays dividendsHighly cyclical earnings
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.